The economic and psychological consequences of diabetes-related hypoglycemic events
are multifold and shared across various parties, including patients and their family or …

Background To conduct a real-word-study-based cost-effectiveness analysis of a GLP-1
receptor agonist (GLP-1RA) versus insulin among type 2 diabetes patients requiring …

Aims To evaluate the cost-effectiveness of glucagon-like peptide-1 receptor agonists (GLP-
1RAs) versus long-acting insulins (LAIs) in patients with type 2 diabetes (T2D) using real …

Diabetes is a chronic, metabolic disease characterized by hyperglycemia, which occurs as a
result of inadequate production or utilization of insulin. Type 2 diabetes (T2D) is the most …

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a class of drugs with potent
glucose-lowering activity. Additionally, some GLP-1 RAs have demonstrated cardiovascular …

Pharmacoeconomics is an important tool for investigating and restructuring healthcare
policies. In India, recent statistical studies have shown that the number of diabetic patients is …

Background Diabetes represents a relevant public health problem worldwide due to its
growing prevalence and socioeconomic burden, principally due to the development of …

Introduction Optimal glycemic management after diabetes onset remains a challenge in
Hispanic/Latino adults with type 2 diabetes (T2D), often resulting in poor health outcomes …

Objective: The objective of this review was to examine the role of adverse drug events
(ADEs) caused by pharmacological interventions in cost-effectiveness models for diabetes …

Type 2 diabetes (T2D) is a metabolic disease that results from insulin resistance or limited
insulin production. The prevalence of T2D disproportionally burdens Indigenous people in …